WHO Temporarily Suspends Trial of Hydroxychloroquine Over Safety Concerns

The World Health Organization is temporarily pausing tests of the anti-malarial drug hydroxychloroquine as a coronavirus treatment in order to review safety concerns, the agency's director-general Tedros Adhanom Ghebreyesu said Monday. From a report: The decision comes after a retrospective review published in The Lancet found that coronavirus patients who took hydroxychloroquine or its related drug chloroquine were more likely to die or develop an irregular heart rhythm that can lead to sudden cardiac death, compared to those who did nothing. The medical journal's review consisted of 96,000 hospitalized patients diagnosed with the coronavirus in six continents, the largest analysis of medical records on the drug, between Dec. 20, 2019, and April 14, 2020. Tedros said that an independent executive panel "agreed to review a comprehensive analysis and critical appraisal of all evidence available globally" regarding hydroxychloroquine in order to determine whether it should continue to be used in WHO's Solidarity Trial, a global effort to test experimental coronavirus treatments.